MMCAP International Inc. SPC and MM Asset Management Inc. filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of Ordinary Shares of Akari Therapeutics, Plc as of September 30, 2026.

Key Highlights

  • Two reporting persons: MMCAP International Inc. SPC (Cayman Islands) and MM Asset Management Inc. (Ontario, Canada) filed jointly as Amendment No. 1.
  • Aggregate beneficial ownership: Each reporting person holds 11,427 American Depository Shares, with each ADS convertible into 80,000 Ordinary Shares, par value $0.000000005.
  • Percent of class: The 11,427 ADS position represents 0.6% of the class, calculated using 155,758,529,533 Ordinary Shares outstanding as of August 13, 2026.
  • Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power, and 11,427 shared voting and shared dispositive power each.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.
  • Ownership threshold: The filing confirms ownership of 5 percent or less of the class.

MMCAP and MM Asset Management Report Joint ADS Position in Akari Therapeutics

According to the filing, MMCAP International Inc. SPC and MM Asset Management Inc. submitted Amendment No. 1 to their Schedule 13G disclosing a combined beneficial interest in Akari Therapeutics, Plc (NASDAQ:AXTX as cited in the filing), whose Ordinary Shares carry CUSIP number 00972G405. The issuer's principal executive offices are listed at 401 E. Jackson Street, Suite 3300, Tampa, FL 33602. The triggering event for the amended filing is dated September 30, 2026.

The filing states that both MMCAP International Inc. SPC and MM Asset Management Inc. each beneficially own 11,427 American Depository Shares, with each ADS convertible into 80,000 Ordinary Shares at a par value of $0.000000005 per share. The percent of class is reported as 0.6%, calculated on a partially diluted basis using 155,758,529,533 Ordinary Shares outstanding as of August 13, 2026, as reported in the issuer's 10-Q filed with the SEC on that date. Neither reporting person holds sole voting or sole dispositive power over any shares; both powers are reported as shared at 11,427 each.

The filing was signed on November 10, 2026, by Ulla Vestergaard, Director of MMCAP International Inc. SPC, and by Hillel Meltz, President of MM Asset Management Inc. Both certify, according to the filing, that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." A Joint Filing Agreement is listed as Exhibit 99.1.

What Was Disclosed

MMCAP International Inc. SPC and MM Asset Management Inc. jointly disclosed beneficial ownership of 11,427 American Depository Shares, representing 0.6% of Akari Therapeutics' Ordinary Shares, in an amended Schedule 13G triggered by an event on September 30, 2026.